Please assess the completion status of the following clinical trial:

Trial Title: Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male, at least 18 years of age~* Has a total NIH-CPSI total score of 15~* Has a NIH-CPSI pain score of 8~* Has had pain in the pelvic region for at least 3 months prior to screening~Exclusion Criteria:~* Has previously participated in a Watson study with silodosin~* Has previously received α-blocked therapy for chronic prostatitis/chronic pelvic pain syndrome or is currently receiving α-blocked therapy for any condition~* Has experience ≥2 urinary tract infections within the previous 12 months~* Has any medical condition that in the opinion of the investigator precludes safe participation in the study~* Has any medical condition that could confound the efficacy evaluation~* Is receiving ketoconazole, or other known potent inhibitors of cytochrome P450 3A4 or any medication in the opinion of the investigator that precludes safe participation in the study~* Is receiving any medication that in the opinion of the investigator that could confound the efficacy evaluation~* Has participated in a study involving the administration of an investigational agent within the past 30 days

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Silodosin 4 mg (Type: EXPERIMENTAL): 4 mg daily
- Silodosin 8 mg (Type: EXPERIMENTAL): Silodosin 8 mg daily
- Placebo (Type: PLACEBO_COMPARATOR): 1 placebo capsule daily

Based on this trial design, predict the completion outcome and termination type (if applicable).